Trega Biosciences Appoints Chief Financial Officer
SAN DIEGO, Jan. 12 /PRNewswire/ -- Trega Biosciences, Inc. (Nasdaq: TRGA) today announced the appointment of Gerard A. Wills, as chief financial officer. Mr. Wills will be responsible for corporate finance, investor relations, corporate communications, information systems and facilities and report to Michael G. Grey, president and chief executive officer.
As Trega's chief financial officer, Mr. Wills brings approximately 20 years of experience in corporate financial management. Most recently he served as vice president of finance and chief financial officer at Molecular Biosystems, Inc. for six years. He was chief adviser to the chief executive officer and chief operations officer on all corporate funding and business development matters.
"Gerry's experience in business development and investor relations as well as financial and strategic management makes him ideal as Trega's chief financial officer," said Grey. "He will add great value to our senior management team."
Trega Biosciences is a drug discovery company, utilizing combinatorial chemistry and other technologies to pursue the discovery of novel, small-molecule drug therapies. The company leverages its technology platform by entering into pharmaceutical alliances, which provide partners with access to Trega's technologies in exchange for licensing fees and potential milestones and royalties, or by establishing joint-discovery alliances with pharmaceutical and biotechnology companies. Trega also uses its drug discovery technologies in its internal development programs, which are currently focused on discovering small molecules acting on melanocortin receptors. Melanocortins are a class of receptors which may be important in the treatment of inflammatory and metabolic diseases. |
